Eman Z Kandeel1, Nahla El Sharkawy2, Marwa Hanafi2, Mohamed Samra3, Azza Kamel2. 1. Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt. Electronic address: eman_kandeel@hotmail.com. 2. Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt. 3. Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Abstract
BACKGROUND: Acute myeloid leukemia (AML) evolves from neoplastic transformation of stem cell disease termed "leukemia stem cells" (LSCs). An unsatisfactory response to AML therapy is determined by the presence of minimal residual disease (MRD). The predominance of LSCs might anticipate sustained MRD results. The present study aimed to demonstrate the effect of LSCs on MRD at induction days 14 and 28 on overall survival (OS) and disease-free survival (DFS) and to compare LSC expression with MRD status. PATIENTS AND METHODS: A total of 84 patients with de novo adult AML underwent testing using LSC panels for CD38/CD123/CD34/CD45 and CD90/CD133/CD45/CD33 and different regular MRD panels. RESULTS: At day 14 after induction, the high expression of CD123 and CD133 had adverse effects on both OS and DFS (P = .004 and P ≤ .001 and P ≤ .001 and P ≤ .001, respectively). Greater expression of CD34+/CD38-/CD123+ resulted in unfavorable OS and DFS (P ≤ .001 for both). Both CD34+/CD38-/CD123+ and CD34-/CD38+/CD123+ expression at day 14 after induction had an adverse effect on DFS only (P < .001 and P = .029, respectively). On multivariate analysis, CD133 expression and MRD status were independent prognostic parameters (hazard ratio [HR], 2.3; 95% confidence interval [CI], 1.2-4.4; P = .015; and HR, 2.9; 95% CI, 1.0-7.9; P = .041). At day 28 after induction, MRD and increased CD123+/CD34-, CD34+/CD38-/CD123+, CD133+/CD33- expression were associated with inferior OS (P = .016, P = .0035, P = .0.002, and P = .002, respectively). MRD and high expression of CD34+CD123+, CD133+/CD33-, CD34+/CD38-/CD123+ were associated with inferior DFS (P < .001, P = .002, P < .001, P < .001, respectively). On multivariate analysis, only CD133+/CD33- expression was the independent prognostic factor (HR, 3.1; 95% CI, 1.5-6.7; P = .003). CONCLUSIONS: Estimation of LSC expression is a sensitive indicator of the response to therapy in adult patients with AML and might be a better prognosticator than the findings from regular MRD panels.
BACKGROUND:Acute myeloid leukemia (AML) evolves from neoplastic transformation of stem cell disease termed "leukemia stem cells" (LSCs). An unsatisfactory response to AML therapy is determined by the presence of minimal residual disease (MRD). The predominance of LSCs might anticipate sustained MRD results. The present study aimed to demonstrate the effect of LSCs on MRD at induction days 14 and 28 on overall survival (OS) and disease-free survival (DFS) and to compare LSC expression with MRD status. PATIENTS AND METHODS: A total of 84 patients with de novo adult AML underwent testing using LSC panels for CD38/CD123/CD34/CD45 and CD90/CD133/CD45/CD33 and different regular MRD panels. RESULTS: At day 14 after induction, the high expression of CD123 and CD133 had adverse effects on both OS and DFS (P = .004 and P ≤ .001 and P ≤ .001 and P ≤ .001, respectively). Greater expression of CD34+/CD38-/CD123+ resulted in unfavorable OS and DFS (P ≤ .001 for both). Both CD34+/CD38-/CD123+ and CD34-/CD38+/CD123+ expression at day 14 after induction had an adverse effect on DFS only (P < .001 and P = .029, respectively). On multivariate analysis, CD133 expression and MRD status were independent prognostic parameters (hazard ratio [HR], 2.3; 95% confidence interval [CI], 1.2-4.4; P = .015; and HR, 2.9; 95% CI, 1.0-7.9; P = .041). At day 28 after induction, MRD and increased CD123+/CD34-, CD34+/CD38-/CD123+, CD133+/CD33- expression were associated with inferior OS (P = .016, P = .0035, P = .0.002, and P = .002, respectively). MRD and high expression of CD34+CD123+, CD133+/CD33-, CD34+/CD38-/CD123+ were associated with inferior DFS (P < .001, P = .002, P < .001, P < .001, respectively). On multivariate analysis, only CD133+/CD33- expression was the independent prognostic factor (HR, 3.1; 95% CI, 1.5-6.7; P = .003). CONCLUSIONS: Estimation of LSC expression is a sensitive indicator of the response to therapy in adult patients with AML and might be a better prognosticator than the findings from regular MRD panels.
Authors: Azza M Kamel; Nahla M Elsharkawy; Eman Z Kandeel; Marwa Hanafi; Mohammed Samra; Randa A Osman Journal: Front Oncol Date: 2022-04-08 Impact factor: 5.738
Authors: Hélène Bonnevaux; Stephane Guerif; Jana Albrecht; Erwan Jouannot; Thibaud De Gallier; Christian Beil; Christian Lange; Wulf Dirk Leuschner; Marion Schneider; Cendrine Lemoine; Anne Caron; Céline Amara; Cédric Barrière; Justine Siavellis; Valérie Bardet; Ernesto Luna; Pankaj Agrawal; Donald R Drake; Ercole Rao; Peter Wonerow; Chantal Carrez; Véronique Blanc; Karl Hsu; Dmitri Wiederschain; Paula G Fraenkel; Angéla Virone-Oddos Journal: Oncoimmunology Date: 2021-08-31 Impact factor: 8.110
Authors: Geoffrey L Uy; Ibrahim Aldoss; Matthew C Foster; Peter H Sayre; Matthew J Wieduwilt; Anjali S Advani; John E Godwin; Martha L Arellano; Kendra L Sweet; Ashkan Emadi; Farhad Ravandi; Harry P Erba; Michael Byrne; Laura Michaelis; Max S Topp; Norbert Vey; Fabio Ciceri; Matteo Giovanni Carrabba; Stefania Paolini; Gerwin A Huls; Mojca Jongen-Lavrencic; Martin Wermke; Patrice Chevallier; Emmanuel Gyan; Christian Récher; Patrick J Stiff; Kristen M Pettit; Bob Löwenberg; Sarah E Church; Erica Anderson; Jayakumar Vadakekolathu; Marianne Santaguida; Michael P Rettig; John Muth; Teia Curtis; Erin Fehr; Kuo Guo; Jian Zhao; Ouiam Bakkacha; Kenneth Jacobs; Kathy Tran; Patrick Kaminker; Maya Kostova; Ezio Bonvini; Roland B Walter; Jan K Davidson-Moncada; Sergio Rutella; John F DiPersio Journal: Blood Date: 2021-02-11 Impact factor: 25.476